JP2022532098A5 - - Google Patents

Info

Publication number
JP2022532098A5
JP2022532098A5 JP2021566041A JP2021566041A JP2022532098A5 JP 2022532098 A5 JP2022532098 A5 JP 2022532098A5 JP 2021566041 A JP2021566041 A JP 2021566041A JP 2021566041 A JP2021566041 A JP 2021566041A JP 2022532098 A5 JP2022532098 A5 JP 2022532098A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cd49d
limb
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021566041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532098A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2020/050445 external-priority patent/WO2020223762A1/en
Publication of JP2022532098A publication Critical patent/JP2022532098A/ja
Publication of JP2022532098A5 publication Critical patent/JP2022532098A5/ja
Ceased legal-status Critical Current

Links

JP2021566041A 2019-05-06 2020-05-06 CD49dに対する阻害オリゴヌクレオチドを使用して筋ジストロフィーを治療する方法 Ceased JP2022532098A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019901540A AU2019901540A0 (en) 2019-05-06 Therapeutic uses and methods
AU2019901540 2019-05-06
PCT/AU2020/050445 WO2020223762A1 (en) 2019-05-06 2020-05-06 Methods for treating muscular dystrophy using inhibitory oligonucleotides to cd49d

Publications (2)

Publication Number Publication Date
JP2022532098A JP2022532098A (ja) 2022-07-13
JP2022532098A5 true JP2022532098A5 (cg-RX-API-DMAC7.html) 2023-05-16

Family

ID=73050454

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021566041A Ceased JP2022532098A (ja) 2019-05-06 2020-05-06 CD49dに対する阻害オリゴヌクレオチドを使用して筋ジストロフィーを治療する方法

Country Status (9)

Country Link
US (1) US20220296631A1 (cg-RX-API-DMAC7.html)
EP (1) EP3965778A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022532098A (cg-RX-API-DMAC7.html)
KR (1) KR20220061915A (cg-RX-API-DMAC7.html)
CN (1) CN114555095A (cg-RX-API-DMAC7.html)
AU (1) AU2020269078A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022208A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138945A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020223762A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100014333A1 (it) * 2021-06-01 2022-12-01 Materias S R L Nuovo impiego terapeutico di inibitori della iodiotironina deiodinasi di tipo 2 (D2)
WO2024159266A1 (en) * 2023-02-01 2024-08-08 Antisense Therapeutics Ltd Combination compositions and methods for treatment of muscular dystrophy
CN119113214B (zh) * 2024-11-14 2025-02-11 四川大学 一种肌肉修复材料及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2728562C (en) * 2008-06-23 2018-10-23 Ety Klinger Methods for treating multiple sclerosis using antisense oligonucleotides
EP2427554B1 (en) * 2009-05-08 2016-11-16 CuRNA, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
EP2467159A1 (en) * 2009-08-20 2012-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
JP2018530560A (ja) * 2015-10-09 2018-10-18 サレプタ セラピューティクス, インコーポレイテッド デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
US11891606B2 (en) * 2017-06-16 2024-02-06 Antisense Therapeutics Ltd Methods for treating multiple sclerosis using antisense oligonucleotides
JP7604361B2 (ja) * 2018-05-04 2024-12-23 アンチセンス セラピューティクス リミテッド 治療での使用及び方法

Similar Documents

Publication Publication Date Title
JP7220259B2 (ja) 改善された局所麻酔のための局所麻酔薬及び血管収縮薬と組み合わせたフェノールtrpv1アゴニストのプロドラッグ
US20160201064A1 (en) Compositions and methods for modulating expression of frataxin
EP2442832B1 (en) Compositions and methods for treatment of multiple sclerosis
JP2020523409A (ja) 筋肉の状態を予防または治療するための組成物および方法
WO2009154777A4 (en) Process for preparing and drying solid rasagiline base
JP2000511561A (ja) 肥満症の処置のためのcntf(毛様体神経成長因子)受容体アクティベーターの使用
JP2022536495A5 (cg-RX-API-DMAC7.html)
JP2023520469A5 (cg-RX-API-DMAC7.html)
JP2013526519A (ja) アンチセンスオリゴヌクレオチドを含む医薬組成物およびそれを使用する方法
US20250223591A1 (en) Syf2 antisense oligonucleotides
EP4658787A2 (en) Syf2 antisense oligonucleotides
AU2022341090B2 (en) Treatment of neurological disorders
WO2015186126A1 (en) Fatty acid bile acid conjugates for treatment of lipodystrophy
KR20220061915A (ko) Cd49d에 대한 억제성 올리고뉴클레오티드를 사용하는 근이영양증의 치료 방법
CN110636847A (zh) 用于预防及治疗肌肉疾病的组合物
US20240277641A1 (en) Methods for treating nervous system disorders with antipurinergic agents
JP2013503908A5 (cg-RX-API-DMAC7.html)
JP2024506041A (ja) 潰瘍性大腸炎を予防、処置、または改善するためのアミセリモド
ES2844899T3 (es) Métodos para el tratamiento de enfermedades de las neuronas motoras
US20250213494A1 (en) Methods and compositions for potentiation of a ligand
US20210186950A1 (en) Combinations comprising tropifexor and cenicriviroc
TW201932114A (zh) 化合物用於炎症介導的視神經病變的治療
EP3908287A1 (en) Treatment of fatty liver disease
HK40113386A (zh) 神经病症的治疗
RU2023117173A (ru) Композиция, содержащая антисмысловой олигонуклеотид, и ее применение для лечения мышечной дистрофии дюшенна